Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis.

ABSTRACT: The rising prevalence of cardiovascular disease worldwide necessitates novel therapeutic approaches to manage atherosclerosis. Intravenously administered nanostructures are a promising noninvasive approach to deliver therapeutics that reduce plaque burden. The drug liver X receptor agonist GW3965 (LXR) can reduce atherosclerosis by promoting cholesterol efflux from plaque but causes liver toxicity when administered systemically at effective doses, thus preventing its clinical use. The ability of peptide amphiphile nanofibers containing apolipoprotein A1-derived targeting peptide 4F to serve as nanocarriers for LXR delivery (ApoA1-LXR PA) in vivo is investigated here. These nanostructures are found to successfully target atherosclerotic lesions in a mouse model within 24 h of injection. Aft

SUBMITTER: Mansukhani NA 

PROVIDER: S-EPMC6579116 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature